eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept

eTheRNA raises EUR 34 million…

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

eTheRNA launches an international consortium…

Safety and immune stimulation data from an intranodal delivery of TriMix mRNA

Safety and immune stimulation data…

Appointment of Chief Financial Officer

Niel (Belgium), 29 May 2019…